Mellor R, Kearnes M, Lancaster K, McLauchlan L, Ritter A. Established tables and emergent huddles: exploring the processes of participation associated with the policy changes to opioid pharmacotherapy treatment in Australia in the context of COVID-19. Contemp Drug Probl. 2022 Sep 8;49(4):385-404. doi: 10.1177/00914509221123001
Chambers TM, Agopian AJ, Lewis RA, Langlois PH, Danysh HE, Weber KA, Shaw GM, Mitchell LE, Lupo PJ. Epidemiology of anophthalmia and microphthalmia: prevalence and patterns in Texas, 1999-2009. Am J Med Genet A. 2018 Sep;176(9):1810-8. doi: 10.1002/ajmg.a.40352
Wheeler A, Raspa M, Bann C, Bishop E, Hessl D, Sacco P, Bailey DBJr. Anxiety, attention problems, hyperactivity, and the aberrant behavior checklist in fragile x syndrome. Am J Med Genet A. 2014 Jan;164A(1):141-55. doi: 10.1002/ajmg.a.36232
Westfall PH, Prillaman B, Ho SY. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials. J Biopharm Stat. 2001;11(3):125-38. doi: 10.1081/BIP-100107653